Well, assuming we're still in the hunt, we'll be s
Post# of 36536
(Total Views: 397)
Posted On: 11/14/2021 10:34:27 PM
Well, assuming we're still in the hunt, we'll be seeing a couple of 10Ks in a matter of hours. I hope to see them by early afternoon, since I'll have a bit of time to look at it while my daughter is in a Dr appt. But I expect we'll see it after the market closes.
I have pretty low expectations for these Ks, since the covered period ended on 7/31. However, I do hope to see:
1) Some revenues. Any revenues. I'd actually be happy if they were able to sell a few syringes of Excellagen and chalk up $10k or so.
2) Evidence of a signed deal with the Excellagen financing party.
3) Some sort of communication that tries to overtly or implicitly tell us what the heck is going on with the silence, what progress is being made on that issue, and maybe a hint of a time frame (probably wishful thinking on the time frame).
4) Other evidence of progress that was made between the May conference call and the end of July: Vaccine IND submittal (if approved, surely that was after 7/31), planning for vaccine clinical testing, any progress with AltuCell or any other sub, etc.
5) Any glimmer of progress on the NGIO IPO.
It's a low bar, so I hope they can clear it with ease.
I do have higher expectations for the 10Q that will be coming out in December. With any luck, we'll be getting some real communication out of Joe and the Team before that.
GLTAL!
I have pretty low expectations for these Ks, since the covered period ended on 7/31. However, I do hope to see:
1) Some revenues. Any revenues. I'd actually be happy if they were able to sell a few syringes of Excellagen and chalk up $10k or so.
2) Evidence of a signed deal with the Excellagen financing party.
3) Some sort of communication that tries to overtly or implicitly tell us what the heck is going on with the silence, what progress is being made on that issue, and maybe a hint of a time frame (probably wishful thinking on the time frame).
4) Other evidence of progress that was made between the May conference call and the end of July: Vaccine IND submittal (if approved, surely that was after 7/31), planning for vaccine clinical testing, any progress with AltuCell or any other sub, etc.
5) Any glimmer of progress on the NGIO IPO.
It's a low bar, so I hope they can clear it with ease.
I do have higher expectations for the 10Q that will be coming out in December. With any luck, we'll be getting some real communication out of Joe and the Team before that.
GLTAL!
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼